Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Pharma (IGC) over the last 13 years, with Q3 2025 value amounting to $1.1 million.

  • Pharma's Non Operating Income rose 240697.67% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 154800.0%. This contributed to the annual value of $325000.0 for FY2025, which is 12727.27% up from last year.
  • According to the latest figures from Q3 2025, Pharma's Non Operating Income is $1.1 million, which was up 240697.67% from $306000.0 recorded in Q2 2025.
  • Over the past 5 years, Pharma's Non Operating Income peaked at $1.1 million during Q3 2025, and registered a low of $4000.0 during Q3 2021.
  • Moreover, its 5-year median value for Non Operating Income was $32000.0 (2023), whereas its average is $127631.6.
  • Per our database at Business Quant, Pharma's Non Operating Income crashed by 9616.25% in 2022 and then surged by 297142.86% in 2025.
  • Quarter analysis of 5 years shows Pharma's Non Operating Income stood at $4000.0 in 2021, then surged by 625.0% to $29000.0 in 2022, then grew by 10.34% to $32000.0 in 2023, then surged by 53.12% to $49000.0 in 2024, then skyrocketed by 2100.0% to $1.1 million in 2025.
  • Its Non Operating Income stands at $1.1 million for Q3 2025, versus $306000.0 for Q2 2025 and $215000.0 for Q1 2025.